Showing results (1-10 of 51) with videos related to
Sort By:
Pageof 6
AIDS Reviews|May 20, 2016
Is It Time for Integrase Inhibitors to be the Preferred Regimen for the First-Line Treatment of HIV-1-Infected Naive Patients?Jean Cyr Yombi, Anton L PozniakJournal of Virus Eradication|October 27, 2016
How can we achieve universal access to low-cost treatment for HIV?Andrew M Hill, Anton L PozniakCurrent Opinion in HIV and AIDS|April 14, 2017
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamideDzintars Gotham, Andrew Hill, Anton L PozniakThe Journal of Antimicrobial Chemotherapy|March 8, 2014
Has the time come to abandon efavirenz for first-line antiretroviral therapy?Francois Raffi, Anton L Pozniak, Mark A WainbergExpert Opinion on Pharmacotherapy|February 28, 2002
Lopinavir/ritonavir (ABT-378/r)Nadeem A Qazi, John F Morlese, Anton L PozniakCurrent Opinion in HIV and AIDS|December 27, 2017
Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trialsAndrew M Hill, Nikkita Mitchell, Sophie Hughes, et al.Journal of Virus Eradication|April 24, 2018
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?Andrew Hill, Sophie L Hughes, Dzintars Gotham, et al.Journal of the International AIDS Society|July 19, 2019
Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?Neesha Rockwood, Maddalena Cerrone, Melissa Barber, et al.Current Opinion in HIV and AIDS|April 15, 2017
When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think TankMarco Vitoria, Nathan Ford, Polly Clayden, et al.Pageof 6